Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis

Sorafenib confers a survival benefit for patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh (CP) A liver cirrhosis. At present, limited data exists with regard to the safety and efficacy of sorafenib in treating CP-B HCC patients. The present study describes the use of sorafenib in...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncol Lett
Glavni autori: FEDERICO, ALESSANDRO, ORDITURA, MICHELE, COTTICELLI, GAETANO, DE SIO, ILARIO, ROMANO, MARCO, GRAVINA, ANTONIETTA GERARDA, DALLIO, MARCELLO, FABOZZI, ALESSIO, CIARDIELLO, FORTUNATO, LOGUERCIO, CARMELA, DE VITA, FERDINANDO
Format: Artigo
Jezik:Inglês
Izdano: D.A. Spandidos 2015
Teme:
Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4356395/
https://ncbi.nlm.nih.gov/pubmed/25789012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2015.2960
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items